GW sues pharmaceutical companies for alleged patent infringement – ​​The GW Hatchet

Media Credit: Hatchet File Photo

The School of Medicine and Health Sciences first developed the drug the pharmaceutical companies plan to sell, which allegedly violates patents held by the University, according to the complaint.

Update: April 1, 2022 at 5:10 p.m.

The University is suing three pharmaceutical companies in federal court in New Jersey to stop the development, importation and sale of a septic shock treatment drug that allegedly infringes patents owned by the University.

In a 59-page lawsuit filed Tuesday in the U.S. District Court in New Jersey, officials allege that Indian pharmaceutical company Gland Pharma Limited, Chinese pharmaceutical company Shanghai Fosun Pharmaceutical and its U.S. subsidiary Fosun Pharma USA are seeking permission to manufacture and to sell a drug that is currently protected by GW’s patents. The University argues that the court should bar the companies from selling the drug while the patents are active and award damages to the University if the companies sell the drugs in the United States.

Officials said the companies should also cover the university’s attorney fees for the lawsuit, according to the complaint.

“Unless defendants are permanently enjoined by this Court, the acts of infringement set forth above will cause plaintiffs irreparable harm for which there is no adequate remedy at law,” the lawsuit states.

The patents in question pertain to a drug known as Giapreza, used to to treat adults in shock – dangerously low blood pressure, according to the European Medicines Agency. In 2019, the University sold part of its rights to sales of the drug, which the School of Medicine and Health Sciences first developed.

La Jolla Pharmaceutical Company, which currently owns the manufacturing rights to Giapreza, joined GW in the lawsuit as a plaintiff.

In a statement in February, La Jolla chief financial officer Michael Jearne said the company received notice from Gland Pharma Limited that month that it had sought Food and Drug Administration approval. to sell “a generic version of GIAPREZA”.

Jearne said the notice from Gland Pharma Limited said its drug sales would not infringe the patents, which are “invalid, unenforceable”. He said the FDA can’t approve Gland’s application for seven and a half years after Giapreza’s initial FDA approval if the district court decides the company infringed the patents.

“The Company intends to vigorously defend its intellectual property rights protecting GIAPREZA,” Jearne said.

University spokeswoman Crystal Nosal did not return a request for comment. Spokespersons for Shanghai Fosun Pharmaceutical, Fosun Pharma USA and Gland Pharma Limited did not immediately return requests for comment.

This post has been updated to include the following:
The post has been updated to include an earlier statement from Jeane.